Integral Health Asset Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Integral Health Asset Management reported a $2.4 bn portfolio of 89 positions to the SEC as of the end of Q2 2026. Its largest positions are RVMD, INSM, CYTK. During the quarter it opened Abbott Laboratories and UnitedHealth Group and exited Astrazeneca.
Sections with a free account
What changed this quarter
94 positions with a change (26 new, 23 added to, 21 trimmed, 24 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- CVS Health+633%more sharesIncreased0.6% → 4.7%
- Axsome Therapeutics+757%more sharesIncreased0.3% → 3.0%
- Astrazeneca−2.0 ppof portfolioSold out2.6% → —
- BrightSpring Health Services−56%fewer sharesReduced2.8% → 1.6%
- Edwards Lifesciences+268%more sharesIncreased0.7% → 2.3%
- Abbott Laboratories+1.5 ppof portfolioNew— → 1.5%
- UnitedHealth Group+1.4 ppof portfolioNew— → 1.4%
- Tenet Healthcare+1.3 ppof portfolioNew— → 1.3%
- Quest Diagnostics+233%more sharesIncreased0.6% → 1.7%
- Spyre Therapeutics+1.2 ppof portfolioNew— → 1.2%
- Novo Nordisk A/s+1.2 ppof portfolioNew— → 1.2%
- Regeneron Pharmaceuticals−53%fewer sharesReduced3.5% → 1.0%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Revolution MedicinesRVMD11.5%
- InsmedINSM7.0%
- CytokineticsCYTK5.6%
- CVS HealthCVS4.7%
- Edgewise TherapeuticsEWTX3.3%
- Vera TherapeuticsVERA3.1%
- Axsome TherapeuticsAXSM3.0%
- Cardinal HealthCAH2.9%
- Roivant SciencesROIV2.9%
- Rhythm PharmaceuticalsRYTM2.5%
- Edwards LifesciencesEW2.3%
- Alignment HealthcareALHC2.0%
- MerckMRK1.8%
- Quest DiagnosticsDGX1.7%
- uniQureQURE1.7%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 89
Q2 2026: 47%
Q2 2026: 24.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (3)
Besides stocks, Integral Health Asset Management declared 1 put (they gain if the stock falls) and 2 calls (they gain if it rises) with a notional of $94.4M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTRevolution MedicinesRVMD$56.2M
- CALLIonis PharmaceuticalsIONSnew this quarter$23.8M
- CALLNovo Nordisk A/sNVOnew this quarter$14.4M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 26, 2026 (high confidence).
The data, as reported: INTEGRAL HEALTH ASSET MANAGEMENT, LLC (CRD 301987): 7.B private funds: 1 hedge (gross assets $60M); 5.D assets by client type: pooled vehicles 100% (of $1.9 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- First Beijing InvestmentInvestment firm · $2.4 bn
- Lansdowne Partners (uk) LLPInvestment firm · $2.4 bn
- Route One InvestmentInvestment firm · $2.4 bn
- Focused InvestorsInvestment firm · $2.4 bn
- Forest Avenue Capital ManagementInvestment firm · $2.4 bn
- Intermede Investment PartnersInvestment firm · $2.4 bn